Drug Profile
Research programme: interleukin-2 analogue - Pivotal BioSciences
Alternative Names: PB 101 - Pivotal BioSciences; PB1Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator University of Southern California
- Class Antineoplastics
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 31 Dec 2019 PB 101 is still in preclinical development
- 15 Jun 2010 Preclinical development is ongoing in USA